BIOMAT Database Logo BIOMAT Database Logo

Indapamide reduces hypertensive left ventricular hypertrophy: an international multicenter study. 1993

R Senior, and J L Imbs, and M Bory, and G Amabile, and B Denis, and F Zannad, and N De Luca, and R Marchegiano, and A Lahiri, and E B Raftery
Department of Cardiology, Northwick Park Hospital, Middlesex, England.

The effect of 6 months of treatment with indapamide (IND, 2.5 mg/day) on regression of left ventricular hypertrophy (LVH), an independent predictor of poor prognosis in hypertension, was compared by echocardiography to that of nifedipine (NFD, 40 mg/day), enalapril (ENL, 20 mg/day), atenolol (ATL, 100 mg/day), and hydrochlorothiazide (HCTZ, 25 mg/day) in four parallel double-blind studies in 151 hypertensive patients with a diastolic blood pressure between 95 and 120 mm Hg and a raised left ventricular mass index (LVMI) (mg/m2) (Devereux). Patients were randomized to IND or comparator following a 2-week washout (1 month in the IND vs. ATL study). Respective baseline and 6-month LVMI values (mg/m2) were: IND (n = 20) vs. HCTZ (n = 20): 151.4 +/- 6.3 and 125.70 +/- 4.6 (p < 0.001) vs. 141.3 +/- 6.6 and 135.6 +/- 8.3 (p = N.S.); IND (n = 22) vs NFD (n = 19): 144.1 +/- 5.3 and 125.1 +/- 4.3 (p < 0.001) vs. 170.4 +/- 6.6 and 148.2 +/- 6.2 (p < 0.001); IND (n = 9) vs. ENL (n = 9): 155.1 +/- 6.3 and 143.4 +/- 5.2 (p < 0.001) vs. 142.0 +/- 6.7 and 130.0 +/- 5.9 (p < 0.001); IND (n = 17) vs. ATL (n = 12): 146.2 +/- 5.1 and 130.8 +/- 6.5 (p < 0.001) vs. 156.7 +/- 8.4 and 142.9 +/- 10.3 (p < 0.01). All drugs significantly reduced diastolic blood pressure, and all except HCTZ induced a significant and similar reduction in left ventricular mass.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D007190 Indapamide A benzamide-sulfonamide-indole derived DIURETIC that functions by inhibiting SODIUM CHLORIDE SYMPORTERS. Metindamide,S-1520,SE-1520,S 1520,S1520,SE 1520,SE1520
D007558 Italy A country in southern Europe, a peninsula extending into the central Mediterranean Sea, northeast of Tunisia. The capital is Rome. Sardinia
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009543 Nifedipine A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure. Adalat,BAY-a-1040,Bay-1040,Cordipin,Cordipine,Corinfar,Fenigidin,Korinfar,Nifangin,Nifedipine Monohydrochloride,Nifedipine-GTIS,Procardia,Procardia XL,Vascard,BAY a 1040,BAYa1040,Bay 1040,Bay1040,Monohydrochloride, Nifedipine,Nifedipine GTIS
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004656 Enalapril An angiotensin-converting enzyme inhibitor that is used to treat HYPERTENSION and HEART FAILURE. Enalapril Maleate,MK-421,MK421,Renitec,Renitek,MK 421,Maleate, Enalapril
D005260 Female Females

Related Publications

R Senior, and J L Imbs, and M Bory, and G Amabile, and B Denis, and F Zannad, and N De Luca, and R Marchegiano, and A Lahiri, and E B Raftery
Hypertensive left ventricular hypertrophy.
March 1989, Southern medical journal,
R Senior, and J L Imbs, and M Bory, and G Amabile, and B Denis, and F Zannad, and N De Luca, and R Marchegiano, and A Lahiri, and E B Raftery
Indapamide regresses, but transdermal clonidine does not regress, left ventricular hypertrophy in hypertensive diabetic patients.
February 1996, The American journal of cardiology,
R Senior, and J L Imbs, and M Bory, and G Amabile, and B Denis, and F Zannad, and N De Luca, and R Marchegiano, and A Lahiri, and E B Raftery
Regression of left ventricular hypertrophy in hypertension with indapamide.
October 1991, American heart journal,
R Senior, and J L Imbs, and M Bory, and G Amabile, and B Denis, and F Zannad, and N De Luca, and R Marchegiano, and A Lahiri, and E B Raftery
Treatment of Hypertensive Left Ventricular Hypertrophy.
January 2018, Current pharmaceutical design,
R Senior, and J L Imbs, and M Bory, and G Amabile, and B Denis, and F Zannad, and N De Luca, and R Marchegiano, and A Lahiri, and E B Raftery
[Left ventricular hypertrophy in hypertensive patients].
September 1994, Annales de cardiologie et d'angeiologie,
R Senior, and J L Imbs, and M Bory, and G Amabile, and B Denis, and F Zannad, and N De Luca, and R Marchegiano, and A Lahiri, and E B Raftery
Left ventricular hypertrophy in hypertensive patients.
January 1989, The American journal of medicine,
R Senior, and J L Imbs, and M Bory, and G Amabile, and B Denis, and F Zannad, and N De Luca, and R Marchegiano, and A Lahiri, and E B Raftery
Detection of hypertensive left ventricular hypertrophy.
January 1985, Hypertension (Dallas, Tex. : 1979),
R Senior, and J L Imbs, and M Bory, and G Amabile, and B Denis, and F Zannad, and N De Luca, and R Marchegiano, and A Lahiri, and E B Raftery
Effects of indapamide in rats with pressure overload left ventricular hypertrophy.
October 2000, Journal of cardiovascular pharmacology,
R Senior, and J L Imbs, and M Bory, and G Amabile, and B Denis, and F Zannad, and N De Luca, and R Marchegiano, and A Lahiri, and E B Raftery
Hypertensive left ventricular hypertrophy risk: beyond adaptive cardiomyocytic hypertrophy.
January 2011, Journal of hypertension,
R Senior, and J L Imbs, and M Bory, and G Amabile, and B Denis, and F Zannad, and N De Luca, and R Marchegiano, and A Lahiri, and E B Raftery
Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg versus enalapril 20 mg: the LIVE study.
October 2000, Journal of hypertension,
Copied contents to your clipboard!